FDA Clearance Tracker · K213875
DRI TM Tricyclics Serum Tox Assay
Last checked: Nov 19, 2026Latest source record: Dec 21, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Dec 21, 2022
Substantially Equivalent
Time to decision
373 days
Received Dec 13, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K213875
- Device name
- DRI TM Tricyclics Serum Tox Assay
- Applicant
- Microgenics Corporation
- Applicant location
- Fremont, CA
- Received
- Dec 13, 2021
- Decided
- Dec 21, 2022
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.3910
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LFH. The earliest in FDA's data is K953761, decided Nov 22, 1995.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K213875
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Microgenics Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K243498 · Decided Dec 11, 2024 · 29 days after receipt
Device type: Enzyme Immunoassay, Benzodiazepine (JXM) · Laboratory Medicine & Pathology
- DRI Ecstasy Plus Assay510(k)
K240670 · Decided Oct 30, 2024 · 233 days after receipt
Device type: Enzyme Immunoassay, Amphetamine (DKZ) · Laboratory Medicine & Pathology
K231020 · Decided Nov 17, 2023 · 221 days after receipt
Device type: U.V. Spectrometry, Tricyclic Antidepressant Drugs (LFH) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.